Abstract:Parkinson's disease has multiple detrimental effects on motor and cognitive systems in the brain. In contrast to motor deficits, cognitive impairments in Parkinson's disease are usually not ameliorated, and can even be worsened, by dopaminergic treatments. Recent evidence has shown potential benefits from restoring other neurotransmitter deficits, including noradrenergic and serotonergic transmission. Here, we study global and regional brain network organization using task-free imaging (also known as resting-state), which minimizes performance confounds and the bias towards predetermined networks. Thirty-three patients with idiopathic Parkinson's disease were studied three times in a double-blinded, placebo-controlled counter-balanced crossover design, following placebo, 40 mg oral atomoxetine (selective noradrenaline reuptake inhibitor) or 30mg oral citalopram (selective serotonin reuptake inhibitor). Neuropsychological assessments were performed outside the scanner. Seventy-six controls were scanned without medication to provide normative data for comparison to the patient cohort. Graph theoretical analysis of task-free brain connectivity, with a random 500-node parcellation, was used to measure the effect of disease in placebo-treated state (versus unmedicated controls) and pharmacological intervention (drug versus placebo). Relative to controls, patients on placebo had executive impairments (reduced fluency and inhibitory control), which was reflected in dysfunctional network dynamics in terms of reduced clustering coefficient, hub degree and hub centrality. In patients, atomoxetine improved fluency in proportion to plasma concentration (P = 0.006, r(2) = 0.24), and improved response inhibition in proportion to increased hub Eigen centrality (P = 0.044, r(2) = 0.14). Citalopram did not improve fluency or inhibitory control, but its influence on network integration and efficiency depended on disease severity: clustering (P = 0.01, r(2) = 0.22), modularity (P = 0.043, r(2) = 0.14) and path length (P = 0.006, r(2) = 0.25) increased in patients with milder forms of Parkinson's disease, but decreased in patients with more advanced disease (Unified Parkinson's Disease Rating Scale motor subscale part III > 30). This study supports the use of task-free imaging of brain networks in translational pharmacology of neurodegenerative disorders. We propose that hub connectivity contributes to cognitive performance in Parkinson's disease, and that noradrenergic treatment strategies can partially restore the neural systems supporting executive function.

Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression

Effects of Antidepressant Treatment on Cognitive Control Network in Patients with Major Depressive Disorder

The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge

Atomoxetine And Citalopram Alter Brain Network Organization In Parkinson'S Disease

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial

The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study

Atomoxetine and citalopram alter brain network organisation in Parkinson’s disease

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression

Depression-related anterior cingulate prefrontal resting state connectivity normalizes following cognitive behavioral therapy

Effect of acute citalopram on self-referential emotional processing and social cognition in healthy volunteers

Striatal Functional Connectivity Alterations after Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder

Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results from the DECIFER Trial

Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder

Effect of Duloxetine on Cognitive Function and Neuroendocrine in Patients with Depression

Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder

Hippocampal-subregion Functional Alterations Associated with Antidepressant Effects and Cognitive Impairments of Electroconvulsive Therapy